Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 EV-to-FCF is -6.88 as of Aug. 20, 2026. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 103 Medical Diagnostics & Research companies, Invicta Diagnostic ranks worse than 970872.82% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Invicta Diagnostic's Enterprise Value is ₹690.2 Mil.
Invicta Diagnostic's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-100.3 Mil. Therefore, Invicta Diagnostic's EV-to-FCF for today is -6.88.
The historical rank and industry rank for Invicta Diagnostic's EV-to-FCF or its related term are showing as below:
NSE:INVICTA'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.12 Med: -4.56 Max: 18.14
Current: -7.3
During the past 3 years, the highest EV-to-FCF of Invicta Diagnostic was 18.14. The lowest was -8.12. And the median was -4.56.
NSE:INVICTA's EV-to-FCF is ranked worse than 100% of 103
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.58
vs NSE:INVICTA: -7.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Invicta Diagnostic's PE Ratio (TTM) for today is calculated as:
Invicta Diagnostic's share price for today is ₹69.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invicta Diagnostic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3.972.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Invicta Diagnostic EV-to-FCF Related Terms
Invicta Diagnostic EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic EV-to-FCF Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
EV-to-FCF
0.00
0.00
-6.05
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
EV-to-FCF
0.00
0.00
0.00
-6.05
NSE:INVICTA vs TMO, DHR, IDXX: EV-to-FCF Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's EV-to-FCF falls into.
Invicta Diagnostic's current Enterprise Value is ₹690.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invicta Diagnostic's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-100.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a EV-to-FCF of -6.88 as of Aug. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Invicta Diagnostic and its competitors. According to the industry distribution chart, Invicta Diagnostic ranks #999999 out of 103 companies in the Medical Diagnostics & Research industry.
Is Invicta Diagnostic's EV-to-FCF too high?
Invicta Diagnostic's current EV-to-FCF is -6.88. Based on the distribution chart, Invicta Diagnostic ranks #999999 out of 103 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #999999 out of 103 companies for EV-to-FCF. This places Invicta Diagnostic in the lower half of its industry. The industry median EV-to-FCF is 27.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 27.58, based on 103 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 27.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current EV-to-FCF is -6.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current EV-to-FCF of -6.88. The current EV-to-FCF is -6.88. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current EV-to-FCF is -6.88 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
